varenicline

Varenicline (CP 526555), a cytisine-based nicotinic ligand, is a potent partial agonist for the α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM and acts as a full agonist for α7 and α3β4 nAChRs, with respective EC50 values of 18 μM and 55 μM [1]. Notably, its effectiveness and potential in smoking cessation treatments are underscored by its pharmacological profile [2].

Hydroxy varenicline, a metabolite of the nicotinic acetylcholine receptor (nAChR) agonist varenicline, functions within the biochemical pathway by interacting with nAChR sites.

Varenicline Hydrochloride is a partial agonist of α4β2 nicotinic receptor.

Varenicline dihydrochloride is a Selective α4β2 nicotinic acetylcholine receptor partial agonist.

Varenicline Tartrate (CP 526555-18) is a benzazepine derivative that functions as an ALPHA4/BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.

Ultrapotent PSEM (uPSEM) agonist for PSAM4-GlyR and PSAM4-5HT3 (Ki = 0.7 nM for PSAM4-GlyR and <10 nM for PSAM4-5HT3). Exhibits >10,000-fold agonist selectivity for PSAM4-GlyR over α7-GlyR, α7-5HT3, and 5HT3-R, and 230-fold selectivity over α4β2 nAChR. Also weak partial agonist (~10 %) at α4β2 nAChR. Retains the potency of varenicline (Cat.No. 3754) for PSAM4-GlyR with enhanced chemogenetic selectivity. Does not act as a substrate for P-glycoprotein pumps. Silences neurons in vivo. Brain-penetrant. Magnus et al (2019) Ultrapotent chemogenetics for research and potential clinical applications. Science doi: 10.1126/science PMID:30872534